4.7 Review

A brief history of long circulating nanoparticles

期刊

ADVANCED DRUG DELIVERY REVIEWS
卷 188, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.addr.2022.114396

关键词

Erythrocytes; Kupffer cell; Liver; Long circulating; Liposomes; Macrophage; Nanoparticles; Opsonins; Polymers

资金

  1. European Union [956544]
  2. DIRNANO programme

向作者/读者索取更多资源

This article provides a brief history of the development of long circulating nanoparticles and highlights important lessons learned in camouflaging nanoparticles to avoid rapid interception by Kupffer cells.
The propensity of the hepatic macrophages (Kupffer cells) to rapidly intercept particulate materials from the blood has been frustrating in redirecting intravenously injected nanomedicines to pathological sites in sufficient quantities to exert appropriate pharmacological effect. The development of long circulating nanoparticles has offered unprecedented opportunities for controlled drug release within vasculature and for drug delivery to sites other than Kupffer cells. These developments were based on mechanistic understanding of complex and integrated body's defences against intruders as well as translation of pro-tective strategies developed by the body's own cells and virulent pathogens against immune attack. Thanks to interdisciplinary and integrated approaches, numerous organic and inorganic nanoparticles with long circulating properties have become available. By long circulation we mean particles that remain in the blood for periods of hours rather than minutes, but blood longevity must be tuned in accordance with therapeutic needs. Here, we provide a brief history of these efforts and highlight important lessons learned in camouflaging nanoparticles with strategies that avoid rapid interception by Kupffer cells.(c) 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据